- Home
- PIII vs LSTA Comparison
PIII vs LSTA Comparison
Compare PIII & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- LSTA
- Stock Information
- Founded
- PIII 2015
- LSTA 1980
- Country
- PIII United States
- LSTA United States
- Employees
- PIII N/A
- LSTA N/A
- Industry
- PIII Medical/Nursing Services
- LSTA Misc Health and Biotechnology Services
- Sector
- PIII Health Care
- LSTA Health Care
- Exchange
- PIII Nasdaq
- LSTA Nasdaq
- Market Cap
- PIII 21.4M
- LSTA 20.9M
- IPO Year
- PIII N/A
- LSTA N/A
- Fundamental
- Price
- PIII $6.37
- LSTA $2.80
- Analyst Decision
- PIII Buy
- LSTA Strong Buy
- Analyst Count
- PIII 2
- LSTA 1
- Target Price
- PIII $16.25
- LSTA $15.00
- AVG Volume (30 Days)
- PIII 5.1K
- LSTA 14.5K
- Earning Date
- PIII 08-06-2025
- LSTA 08-11-2025
- Dividend Yield
- PIII N/A
- LSTA N/A
- EPS Growth
- PIII N/A
- LSTA N/A
- EPS
- PIII N/A
- LSTA N/A
- Revenue
- PIII $1,485,192,000.00
- LSTA $1,000,000.00
- Revenue This Year
- PIII N/A
- LSTA N/A
- Revenue Next Year
- PIII $6.01
- LSTA N/A
- P/E Ratio
- PIII N/A
- LSTA N/A
- Revenue Growth
- PIII 9.79
- LSTA N/A
- 52 Week Low
- PIII $6.00
- LSTA $1.87
- 52 Week High
- PIII $32.54
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- PIII 33.55
- LSTA 59.64
- Support Level
- PIII $6.00
- LSTA $2.36
- Resistance Level
- PIII $6.35
- LSTA $2.69
- Average True Range (ATR)
- PIII 0.22
- LSTA 0.22
- MACD
- PIII 0.03
- LSTA 0.02
- Stochastic Oscillator
- PIII 21.62
- LSTA 62.50
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.